{
    "clinical_study": {
        "@rank": "8458", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with\n      stage IV breast cancer."
        }, 
        "brief_title": "Bryostatin 1 in Treating Patients With Stage IV Breast Cancer", 
        "completion_date": {
            "#text": "April 2004", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the clinical response of patients with stage IV breast cancer to bryostatin\n           1.\n\n        -  Determine the efficacy of this regimen in these patients.\n\n        -  Estimate the pharmacokinetic parameters of bryostatin 1 when given as 24 hour infusion.\n\n        -  Determine the ability of this regimen to regulate lymphocyte function in these\n           patients.\n\n        -  Determine the effect of this regimen on platelet function and protein kinase C activity\n           in these patients.\n\n      OUTLINE: Patients receive bryostatin 1 IV over 24 hours. Treatment continues weekly in the\n      absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 4-8 weeks for tumor response.\n\n      PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Unequivocal diagnosis of metastatic breast cancer\n\n          -  Bidimensionally measurable disease\n\n          -  No uncontrolled CNS metastases\n\n          -  No disease that is evaluable only, including blastic bone disease, malignant ascites,\n             and malignant pleural effusion\n\n          -  Hormone receptor status:\n\n               -  Not specified\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Menopausal status:\n\n          -  Not specified\n\n        Performance status:\n\n          -  SWOG 0-2 OR\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  At least 18 weeks\n\n        Hematopoietic:\n\n          -  Platelet count at least 50,000/mm^3\n\n          -  PT and PTT within normal limits\n\n          -  Neutrophil count at least 2,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.2 mg/dL\n\n          -  Transaminases no greater than 3 times normal\n\n        Renal:\n\n          -  Creatinine no greater than 1.6 mg/dL OR\n\n          -  Creatinine clearance at least 70 mL/min\n\n        Other:\n\n          -  No active infections requiring antibiotics\n\n          -  No viral hepatitis allowed\n\n          -  Seronegative for hepatitis B or C\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception during and for 2 months following\n             study participation\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No concurrent immunotherapy\n\n        Chemotherapy:\n\n          -  2 prior chemotherapy regimens for metastatic disease allowed as adjuvant therapy or\n             for advanced disease (may include high dose chemotherapy with stem cell support)\n\n          -  At least 4 weeks since prior chemotherapy\n\n          -  At least 6 weeks since prior nitrosourea or mitomycin therapy\n\n          -  No other concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  2 prior hormonal therapy regimens for metastatic disease as adjuvant therapy or for\n             advanced diseases allowed\n\n          -  At least 2 weeks since prior hormonal therapy (at least 4 weeks in case of disease\n             progression while receiving hormonal therapy after initial response)\n\n          -  No concurrent hormonal therapy except oral contraceptives\n\n          -  No concurrent use of steroids except for management of severe or life- threatening\n             toxic effects arising from bryostatin 1\n\n        Radiotherapy:\n\n          -  At least 2 weeks since prior radiotherapy\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  No concurrent use of drugs known to interfere with platelet function, such as aspirin\n             or NSAIDs (including ibuprofen)\n\n          -  No concurrent use of anticoagulants\n\n          -  At least 2 weeks since prior use of aspirin\n\n          -  At least 2 days since prior use of NSAIDS\n\n          -  Concurrent use of acetaminophen to control pain is allowed\n\n          -  If acetaminophen inadequate for pain control, concurrent use of oral narcotics such\n             as codeine or oxycodone is allowed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003205", 
            "org_study_id": "97-0751.cc", 
            "secondary_id": [
                "UCHSC-97751", 
                "NCI-T97-0063"
            ]
        }, 
        "intervention": {
            "intervention_name": "bryostatin 1", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Bryostatin 1"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "stage IV breast cancer", 
            "recurrent breast cancer"
        ], 
        "lastchanged_date": "May 28, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UCHSC-97751"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Denver", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80010"
                }, 
                "name": "University of Colorado Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Trial of Bryostatin-1 for the Treatment of Stage IV Breast Cancer", 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Andrew S. Kraft, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003205"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2002"
    }, 
    "geocoordinates": {
        "University of Colorado Cancer Center": "39.739 -104.985"
    }
}